Clinical significance and outcomes of bilateral and unilateral recurrent laryngeal nerve lymph node dissection in esophageal squamous cell carcinoma: A large-scale retrospective cohort study.
esophageal squamous cell carcinoma
inverse probability of treatment weighting
morbidity
prognosis
recurrent laryngeal nerve lymph nodes dissection
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
17
09
2021
received:
01
08
2021
accepted:
15
10
2021
pubmed:
18
2
2022
medline:
9
4
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
The survival benefits of recurrent laryngeal nerve lymph node dissection (RLNLD) in esophageal squamous cell carcinoma (ESCC) are still under debate, and the prognostic value of unilateral RLNLD has been rarely studied. Therefore, the aim of the present study was to investigate the clinical significance and outcomes of RLNLD in ESCC in a large-scale cohort study, to shed light on the outcomes of unilateral RLNLD, and to identify the factors that affect the prognostic outcome of RLNLD. We retrospectively reviewed 1153 patients with thoracic ESCC who underwent right thoracotomy with lymphadenectomy. The impact of RLNLD on disease-free survival (DFS) and overall survival (OS) was estimated using the Kaplan-Meier method and Cox proportional hazard models. Inverse probability of treatment weighting (IPTW) was performed to adjust for differences in baseline variables in pairwise comparisons. Subgroup analysis of survival and postoperative complications was conducted for selective RLNLD. RLN lymph node (LN) metastasis was independently associated with tumor location and most other LN station metastases. RLNLD was an independent prognostic factor for DFS and OS. Both patients who underwent unilateral and bilateral RLNLD had significantly better DFS and OS than the non-RLNLD patients. Furthermore, pairwise comparisons with IPTW confirmed these results, and we found that patients who underwent bilateral RLNLD had better survival than those who underwent unilateral RLNLD. However, subgroup analysis showed that there was no survival benefit and higher morbidity after bilateral RLNLD for patients with cancer in the lower thoracic esophagus, and elderly and female patients. RLN LN metastasis is very frequent in ESCC, and both unilateral and bilateral RLNLD have considerable survival benefits. Selective RLNLD with better survival and lower morbidity was recommend for some defined subgroups.
Sections du résumé
BACKGROUND
The survival benefits of recurrent laryngeal nerve lymph node dissection (RLNLD) in esophageal squamous cell carcinoma (ESCC) are still under debate, and the prognostic value of unilateral RLNLD has been rarely studied. Therefore, the aim of the present study was to investigate the clinical significance and outcomes of RLNLD in ESCC in a large-scale cohort study, to shed light on the outcomes of unilateral RLNLD, and to identify the factors that affect the prognostic outcome of RLNLD.
METHODS
We retrospectively reviewed 1153 patients with thoracic ESCC who underwent right thoracotomy with lymphadenectomy. The impact of RLNLD on disease-free survival (DFS) and overall survival (OS) was estimated using the Kaplan-Meier method and Cox proportional hazard models. Inverse probability of treatment weighting (IPTW) was performed to adjust for differences in baseline variables in pairwise comparisons. Subgroup analysis of survival and postoperative complications was conducted for selective RLNLD.
RESULTS
RLN lymph node (LN) metastasis was independently associated with tumor location and most other LN station metastases. RLNLD was an independent prognostic factor for DFS and OS. Both patients who underwent unilateral and bilateral RLNLD had significantly better DFS and OS than the non-RLNLD patients. Furthermore, pairwise comparisons with IPTW confirmed these results, and we found that patients who underwent bilateral RLNLD had better survival than those who underwent unilateral RLNLD. However, subgroup analysis showed that there was no survival benefit and higher morbidity after bilateral RLNLD for patients with cancer in the lower thoracic esophagus, and elderly and female patients.
CONCLUSION
RLN LN metastasis is very frequent in ESCC, and both unilateral and bilateral RLNLD have considerable survival benefits. Selective RLNLD with better survival and lower morbidity was recommend for some defined subgroups.
Identifiants
pubmed: 35174645
doi: 10.1002/cam4.4399
pmc: PMC8986140
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1617-1629Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
J Thorac Dis. 2019 Jul;11(7):2868-2877
pubmed: 31463116
J Clin Oncol. 2018 Oct 10;36(29):2935-2942
pubmed: 30148659
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):1-5
pubmed: 30678409
J Am Coll Surg. 1997 Sep;185(3):244-9
pubmed: 9291401
Ann Surg Oncol. 2010 Jul;17(7):1721-4
pubmed: 20369299
Dis Esophagus. 2011 Jan;24(1):33-8
pubmed: 20626450
Eur J Surg Oncol. 2005 Apr;31(3):277-81
pubmed: 15780563
World J Surg. 2003 May;27(5):571-9
pubmed: 12715226
Zhonghua Zhong Liu Za Zhi. 2015 Nov;37(11):841-4
pubmed: 26887515
J Clin Oncol. 2018 Sep 20;36(27):2796-2803
pubmed: 30089078
Cancer Med. 2022 Apr;11(7):1617-1629
pubmed: 35174645
Eur J Cardiothorac Surg. 2007 Feb;31(2):154-60
pubmed: 17145185
Interact Cardiovasc Thorac Surg. 2015 Jan;20(1):41-6
pubmed: 25312996
J Am Coll Surg. 2000 Sep;191(3):232-7
pubmed: 10989896
J Thorac Dis. 2016 Oct;8(10):2803-2812
pubmed: 27867556
Ann Thorac Surg. 2013 Jun;95(6):1930-7
pubmed: 23642437
Esophagus. 2020 Jan;17(1):33-40
pubmed: 31428901
Ann Thorac Surg. 2011 Sep;92(3):1091-7
pubmed: 21704967
Zhonghua Wei Chang Wai Ke Za Zhi. 2015 Sep;18(9):867-70
pubmed: 26404679
J Gastrointest Surg. 2012 Apr;16(4):715-21
pubmed: 22258878
Br J Cancer. 2013 Nov 26;109(11):2894-903
pubmed: 24201750
Dis Esophagus. 2015 Jan;28(1):68-77
pubmed: 23796327
JAMA Surg. 2016 Jan;151(1):32-9
pubmed: 26331431
Ann Surg. 2009 Aug;250(2):206-9
pubmed: 19638911
J BUON. 2017 Nov-Dec;22(6):1533-1539
pubmed: 29332349
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
J Gastrointest Surg. 2014 Jan;18(1):187-93
pubmed: 24241966